People who have not adequately responded to other treatment for a certain type of non-Hodgkin's lymphoma may benefit from Bexxar® (tositumomab). This medicine is also approved for use in people whose cancer has returned. This drug is available by prescription and is only approved for use in adults age 18 and older.
Specifically, Bexxar treatment is reserved for people who have slow-growing, follicular or transformed non-Hodgkin's lymphoma that expresses a certain antigen known as the CD20 antigen.
Bexxar works by binding to the CD20 antigen found on the surface of healthy cells and cancerous B-cells (a type of white blood cell). By binding to the CD20 antigen, Bexxar signals the body to destroy the B-cells. Bexxar is also linked to a radioactive element which emits radiation to destroy both the B-cell the medicine is attached to and surrounding B-cells.